Immuno-Oncology (IO)-Thematic Intelligence Market - 2025-2033

April 2026 | 243 pages | ID: I351F61750FEEN
DataM Intelligence

Abstracts

The Immuno-Oncology (IO)-Thematic Intelligence Market was valued at USD 7.78 billion in 2025 and is anticipated to reach USD 21.53 billion by 2033, at a CAGR of 0.148 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Immuno-Oncology (IO)-Thematic Intelligence Market.

This report delivers a comprehensive overview of the Immuno-Oncology (IO)-Thematic Intelligence Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Immuno-Oncology (IO)-Thematic Intelligence Market. The Immuno-Oncology (IO)-Thematic Intelligence Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

Immuno-Oncology (IO)-Thematic Intelligence Market Scope:

By Type

• Cytokines
• Bispecific Antibodies
• Cancer Vaccines
• Cell Therapies
• Immune Checkpoint Inhibitors
• Oncolytic Viruses

By Indication

• Melanoma
• Kidney Cancer
• Liver Cancer
• Non-Small Cell Lung Cancer (NSCLC)
• Colorectal Cancer
• Others

By End User

• Pharmaceutical and Biotechnology companies
• Research Institutions
• Others

Key Players

• Thermofisher Scientific
• Merck & Co
• Bristol Myers Squibb
• F. Hoffmann-LA Roche Ltd
• AstraZeneca
• Novartis
• Eli Lilly
• Regeneron Pharmaceuticals
• GSK
• Fresenius Kabi

Major Highlights

This report delivers a comprehensive overview of the Immuno-Oncology (IO)-Thematic Intelligence Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Immuno-Oncology (IO)-Thematic Intelligence Market. The Immuno-Oncology (IO)-Thematic Intelligence Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rise in technological advancements in immunotherapy
    4.1.1.2. Rise in clinical trials and approval of IO therapies
  4.1.2. Restraints
    4.1.2.1. Overuse of combination therapies
    4.1.2.2. XX
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. BY TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  6.1.2. Market Attractiveness Index, By Type
6.2. Cytokines*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Bispecific Antibodies
6.4. Cancer Vaccines
6.5. Cell Therapies
6.6. Immune Checkpoint Inhibitors
6.7. Oncolytic Viruses

7. BY INDICATION

7.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.2. Market Attractiveness Index, By Indication
7.3. Melanoma*
  7.3.1. Introduction
  7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Kidney Cancer
7.5. Liver Cancer
7.6. Non-Small Cell Lung Cancer (NSCLC)
7.7. Colorectal Cancer
7.8. Others

8. BY END USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  8.1.2. Market Attractiveness Index, By End User
8.2. Pharmaceutical and Biotechnology companies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Research Institutions
8.4. Others

9. BY REGION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.2.6.1. U.S.
    9.2.6.2. Canada
    9.2.6.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.3.6.1. Germany
    9.3.6.2. UK
    9.3.6.3. France
    9.3.6.4. Italy
    9.3.6.5. Spain
    9.3.6.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.4.6.1. Brazil
    9.4.6.2. Argentina
    9.4.6.3. Rest of South America
9.5. Asia-Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.5.6.1. China
    9.5.6.2. India
    9.5.6.3. Japan
    9.5.6.4. Australia
    9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Thermofisher Scientific*
  11.1.1. Company Overview
  11.1.2. Product Portfolio and Description
  11.1.3. Financial Overview
  11.1.4. Key Developments
11.2. Merck & Co
11.3. Bristol Myers Squibb
11.4. F. Hoffmann-LA Roche Ltd
11.5. AstraZeneca
11.6. Novartis
11.7. Eli Lilly
11.8. Regeneron Pharmaceuticals
11.9. GSK
11.10. Fresenius Kabi (LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services
12.2. Contact Us